Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2020 10:25 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: CORRECTION: SHARE CAPITAL DECREASE REGISTERED – NEW PAR VALUE

Reference is made to the decision by the general meeting of Hofseth BioCare ASA (the "Company") on 25 May 2020 to decrease the share capital with NOK 325,783,142.19 through a reduction of the par...
August 12, 2020 09:27 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SHARE CAPITAL DECREASE REGISTERED – NEW PAR VALUE

Reference is made to the decision by the general meeting of Hofseth BioCare ASA (the "Company") on 25 May 2020 to decrease the share capital with NOK 325,783,142.19 through a reduction of the par...
June 30, 2020 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC starts its accelerated COVID-19 Phase 2 clinical trial of OmeGo® salmon oil to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration

Reference is made to the stock exchange notice on 26 May 2020 and Hofseth BioCare ASA (“HBC”) announces that Health Canada has approved its accelerated phase 2 investigational trial protocol of CARDIO...
May 26, 2020 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC har startet protokollutvikling for en akselerert klinisk fase 2-studie med OmeGo® for å redusere akutt lungesvikt og behovet for kunstig åndedrett hos COVID-19 pasienter

Hofseth BioCare ASA (“HBC”) forbereder en protokoll med KGK Science til Health Canada for å gjennomføre en fase 2 klinisk studie som skal vurdere OmeGo® i form av HBCs ferdigprodukt CARDIO...
May 26, 2020 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients

Hofseth BioCare ASA (“HBC”) is preparing an investigational protocol with KGK Science into Health Canada to conduct a Phase 2 clinical trial assessing OmeGo® in the form of our branded product CARDIO...
May 25, 2020 05:55 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: Completed Annual General Meeting

The AGM in Hofseth BioCare ASA were held in Havnegata 11, Ålesund today on Monday 25 May 2020. All the matters were decided according to the proposals in the notice. Please find the minutes from the...
May 22, 2020 06:26 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA:

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 ...
May 22, 2020 06:26 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: Proxy Rights at Annual General Meeting

Ola Holen, Chairman of the Board of Hofseth BioCare ASA, has in connection to the upcoming Annual General Meeting on 25 May 2020, received proxy rights from shareholders representing 158 596 305...
May 15, 2020 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: Preclinical research with OmeGo® demonstrates potential to treat eosinophilic asthma

Hofseth BioCare ASA (“HBC”) recently filed a US patent application (630063274 04/07/2020) on minor components in OmeGo® salmon oil that significantly attenuate respiratory eosinophilic inflammation,...
May 15, 2020 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: First Quarter 2020 Financial Report

HBC had operating revenues of NOK 18.5m (NOK 14.7m) in the first quarter of 2020. Cost of Goods Sold (CoGS) amounted to NOK 6.2m (NOK 10.9m) in the period. Operational profit (EBITDA) for the first...